InMed Pharmaceuticals Inc (INM) - Total Liabilities

Latest as of March 2026: $2.24 Billion USD

Based on the latest financial reports, InMed Pharmaceuticals Inc (INM) has total liabilities worth $2.24 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

InMed Pharmaceuticals Inc - Total Liabilities Trend (2001–2025)

This chart illustrates how InMed Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See INM net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

InMed Pharmaceuticals Inc Competitors by Total Liabilities

The table below lists competitors of InMed Pharmaceuticals Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Majedie Investments LSE:MAJE	UK	GBX813.00K
Korab Resources Ltd AU:KOR	Australia	AU$4.53 Million
British Smaller Companies Vct 2 Plc LSE:BSC	UK	GBX515.00K
Warpaint London PLC LSE:W7L	UK	GBX17.83 Million
ELEMENT NUTR.SCIENCES F:93X	Germany	€6.80 Million
Starbreeze AB (publ) ST:STAR-A	Sweden	Skr116.45 Million
AGM Group Holdings Inc Class A NASDAQ:AGMH	USA	$28.66 Million
Aker Carbon Capture ASA OL:ACC	Norway	Nkr100.00 Million

Liability Composition Analysis (2001–2025)

This chart breaks down InMed Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see InMed Pharmaceuticals Inc market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.11	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.33	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.25	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how InMed Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for InMed Pharmaceuticals Inc (2001–2025)

The table below shows the annual total liabilities of InMed Pharmaceuticals Inc from 2001 to 2025.

Year	Total Liabilities	Change
2025-06-30	$2.92 Million	-18.32%
2024-06-30	$3.58 Million	+33.95%
2023-06-30	$2.67 Million	-44.06%
2022-06-30	$4.78 Million	+60.58%
2021-06-30	$2.97 Million	+54.55%
2020-06-30	$1.92 Million	+61.64%
2019-06-30	$1.19 Million	+66.96%
2018-06-30	$713.02K	+150.85%
2017-06-30	$284.24K	-37.69%
2016-06-30	$456.17K	+629.77%
2015-06-30	$62.51K	-10.84%
2014-06-30	$70.11K	+42.48%
2013-06-30	$49.20K	+10.35%
2012-06-30	$44.59K	-3.49%
2011-06-30	$46.20K	-96.38%
2010-06-30	$1.28 Million	+21.19%
2009-06-30	$1.05 Million	-30.63%
2008-06-30	$1.52 Million	+12.29%
2007-06-30	$1.35 Million	+19.05%
2006-06-30	$1.14 Million	-31.31%
2005-06-30	$1.66 Million	+111.84%
2004-06-30	$781.44K	-15.24%
2003-06-30	$921.99K	+1138.43%
2002-06-30	$74.45K	-84.90%
2001-06-30	$493.02K	--

About InMed Pharmaceuticals Inc

NASDAQ:INM USA Drug Manufacturers - Specialty & Generic

Market Cap

$5.00 Million

Market Cap Rank

#29904 Global

#6013 in USA

Share Price

$1.51

Change (1 day)

-2.58%

52-Week Range

$0.62 - $3.38

All Time High

$31185.00